Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
treatment symbols : Alny save search
Alnylam Announces Receipt of Complete Response Letter from U.S. FDA for Supplemental New Drug Application for Patisiran for the Treatment of the Cardiomyopathy of ATTR Amyloidosis
Published: 2023-10-09 (Crawled : 14:30) - biospace.com/
SNY | News | $47.125 1.78% 1.75% 2.1M
|
Health Technology
|
| O: 0.19%
H: 0.0%
C: 0.0%
ALNY | $145.78 0.95% 0.94% 390K
|
Health Technology
|
| O: -4.06%
H: 2.17%
C: -0.83%
fda drug treatment application response
Alnylam Announces Positive Outcome of FDA Advisory Committee Meeting on Patisiran for the Treatment of the Cardiomyopathy of ATTR Amyloidosis
Published: 2023-09-13 (Crawled : 22:00) - biospace.com/
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: -1.8%
H: 0.0%
C: 0.0%
SNY | News | $47.125 1.78% 1.75% 2.1M
|
Health Technology
|
| O: -0.99%
H: 0.0%
C: 0.0%
fda positive treatment meeting
Alnylam Stock Trading Halted Today; FDA Advisory Committee to Review Supplemental New Drug Application for Patisiran for the Treatment of the Cardiomyopathy of ATTR Amyloidosis
Published: 2023-09-13 (Crawled : 12:00) - biospace.com/
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: -1.8%
H: 0.0%
C: 0.0%
SNY | News | $47.125 1.78% 1.75% 2.1M
|
Health Technology
|
| O: -0.99%
H: 0.0%
C: 0.0%
fda drug review treatment application
Advancements in Diagnosis and Treatment Fuel Rising Prevalence of Thalassemia, Driving Market to 2028
Published: 2023-08-25 (Crawled : 03:00) - prnewswire.com
GLAXF | News | $20.2 -14.18% 510
|
Health Technology
|
| O: 2.25%
H: 0.0%
C: 0.0%
NVS | News | $95.12 0.81% -1.18% 2.4M
|
Health Technology
|
| O: 0.67%
H: 0.37%
C: 0.26%
GSK | News | $40.59 2.11% -0.36% 3.8M
|
Health Technology
|
| O: 0.67%
H: 0.45%
C: 0.2%
SGMO | News | $0.5151 0.7% 0.7% 1.3M
|
Health Technology
|
| O: -3.19%
H: 0.0%
C: 0.0%
IONS | $41.08 0.98% 0.97% 670K
|
Health Technology
|
| O: 0.0%
H: 1.68%
C: 1.28%
EDIT | News | $5.62 2.37% 2.31% 1.7M
|
Health Technology
|
| O: 0.11%
H: 1.25%
C: -0.57%
ALNY | $145.78 0.95% 0.94% 390K
|
Health Technology
|
| O: -0.12%
H: 2.12%
C: 1.45%
treatment market
Agios Announces Exclusive Worldwide License Agreement for Novel siRNA for the Potential Treatment of Polycythemia Vera
Published: 2023-08-03 (Crawled : 11:00) - globenewswire.com
ALNY | $145.78 0.95% 0.94% 390K
|
Health Technology
|
| O: -1.35%
H: 5.58%
C: 4.38%
AGIO | $30.21 2.3% 2.25% 840K
|
Health Technology
|
| O: -2.4%
H: 5.98%
C: 2.81%
license treatment potential agreement
Alnylam Announces Partnership with Roche to Co-Develop and Co-Commercialize Zilebesiran, an Investigational RNAi Therapeutic for the Treatment of Hypertension in Patients with High Cardiovascular Risk
Published: 2023-07-24 (Crawled : 06:00) - biospace.com/
SNY | News | $47.125 1.78% 1.75% 2.1M
|
Health Technology
|
| O: -0.88%
H: 0.0%
C: 0.0%
ALNY | $145.78 0.95% 0.94% 390K
|
Health Technology
|
| O: 0.06%
H: 0.0%
C: 0.0%
partnership treatment risk hypertension roche cardiovascular
Alnylam Announces Date of Planned FDA Advisory Committee Meeting for ONPATTRO® (patisiran) for the Treatment of the Cardiomyopathy of ATTR Amyloidosis
Published: 2023-06-30 (Crawled : 14:00) - biospace.com/
SNY | News | $47.125 1.78% 1.75% 2.1M
|
Health Technology
|
| O: 0.94%
H: 0.0%
C: 0.0%
ALNY | $145.78 0.95% 0.94% 390K
|
Health Technology
|
| O: 1.45%
H: 1.03%
C: -2.01%
onpattro fda treatment meeting
Pozelimab (C5 Antibody) BLA for Treatment of Children and Adults with Ultra-rare CHAPLE Disease Accepted for FDA Priority Review
Published: 2023-02-21 (Crawled : 15:00) - globenewswire.com
SNY | News | $47.125 1.78% 1.75% 2.1M
|
Health Technology
|
| O: 0.79%
H: 0.0%
C: 0.0%
REGN | News | $899.71 0.32% 0.32% 340K
|
Health Technology
|
| O: -0.09%
H: 0.59%
C: -0.21%
ALNY | $145.78 0.95% 0.94% 390K
|
Health Technology
|
| O: -2.68%
H: 0.6%
C: -7.83%
treatment fda disease children review
Alnylam Announces U.S. Food and Drug Administration (FDA) Acceptance of Supplemental New Drug Application for ONPATTRO® (patisiran) for the Treatment of the Cardiomyopathy of ATTR Amyloidosis
Published: 2023-02-21 (Crawled : 14:00) - biospace.com/
SNY | News | $47.125 1.78% 1.75% 2.1M
|
Health Technology
|
| O: 0.79%
H: 0.0%
C: 0.0%
ALNY | $145.78 0.95% 0.94% 390K
|
Health Technology
|
| O: -2.68%
H: 0.6%
C: -7.83%
onpattro treatment drug application food
Alnylam Submits CTA Application for ALN-KHK, an Investigational RNAi Therapeutic for the Treatment of Type 2 Diabetes
Published: 2022-12-21 (Crawled : 13:20) - biospace.com/
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: 6.05%
H: 2.65%
C: 0.66%
SNY | News | $47.125 1.78% 1.75% 2.1M
|
Health Technology
|
| O: 2.63%
H: 0.0%
C: 0.0%
ALNY | $145.78 0.95% 0.94% 390K
|
Health Technology
|
| O: -0.05%
H: 2.34%
C: 1.64%
treatment application diabetes
Alnylam Submits Supplemental New Drug Application (sNDA) to U.S. Food and Drug Administration (FDA) for ONPATTRO® (patisiran) for the Treatment of the Cardiomyopathy of ATTR Amyloidosis
Published: 2022-12-08 (Crawled : 22:00) - biospace.com/
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: 0.5%
H: 0.16%
C: 0.16%
SNY | News | $47.125 1.78% 1.75% 2.1M
|
Health Technology
|
| O: -1.32%
H: 0.0%
C: 0.0%
ALNY | $145.78 0.95% 0.94% 390K
|
Health Technology
|
| O: 0.43%
H: 3.16%
C: 2.44%
onpattro treatment drug application food
Vir Biotechnology Announces First Patient Dosed in the Phase 2 SOLSTICE Trial Evaluating VIR-2218 and VIR-3434 for the Treatment of Chronic Hepatitis D Virus Infection
Published: 2022-09-22 (Crawled : 13:20) - biospace.com/
VIR | $8.11 2.01% 1.97% 1.1M
|
Health Technology
|
| O: -1.55%
H: 2.68%
C: 1.2%
ALNY | $145.78 0.95% 0.94% 390K
|
Health Technology
|
| O: -0.53%
H: 0.0%
C: -1.26%
vir-2218 treatment hepatitis vir-3434 virus trial infection phase 2
Alnylam Receives Approval in Europe for AMVUTTRA® (vutrisiran) for the Treatment of Hereditary Transthyretin-mediated (hATTR) Amyloidosis in Adult Patients with Stage 1 or Stage 2 Polyneuropathy
Published: 2022-09-20 (Crawled : 12:00) - biospace.com/
SNY | News | $47.125 1.78% 1.75% 2.1M
|
Health Technology
|
| O: -1.18%
H: 0.0%
C: 0.0%
ALNY | $145.78 0.95% 0.94% 390K
|
Health Technology
|
| O: 0.0%
H: 1.68%
C: -1.85%
amvuttra treatment europe approval
Alnylam Reports Positive Results from Phase 2 Study of Investigational Cemdisiran for the Treatment of IgA Nephropathy
Published: 2022-08-29 (Crawled : 13:00) - biospace.com/
SNY | News | $47.125 1.78% 1.75% 2.1M
|
Health Technology
|
| O: -1.08%
H: 0.0%
C: 0.0%
REGN | News | $899.71 0.32% 0.32% 340K
|
Health Technology
|
| O: -0.64%
H: 1.24%
C: 0.07%
ALNY | $145.78 0.95% 0.94% 390K
|
Health Technology
|
| O: -0.56%
H: 1.41%
C: -0.34%
treatment nephropathy positive study phase 2
Alnylam Announces FDA Approval of AMVUTTRA™ (vutrisiran), an RNAi Therapeutic for the Treatment of the Polyneuropathy of Hereditary Transthyretin-Mediated Amyloidosis in Adults
Published: 2022-06-14 (Crawled : 07:00) - biospace.com/
SNY | News | $47.125 1.78% 1.75% 2.1M
|
Health Technology
|
| O: -1.73%
H: 0.0%
C: 0.0%
ALNY | $145.78 0.95% 0.94% 390K
|
Health Technology
|
| O: 0.77%
H: 6.48%
C: 3.71%
treatment fda approval
Alnylam Reports Positive Topline Results from Phase 2 Study of Investigational Cemdisiran for the Treatment of IgA Nephropathy
Published: 2022-06-09 (Crawled : 12:00) - biospace.com/
SNY | News | $47.125 1.78% 1.75% 2.1M
|
Health Technology
|
| O: -0.88%
H: 0.0%
C: 0.0%
ALNY | $145.78 0.95% 0.94% 390K
|
Health Technology
|
| O: 1.59%
H: 0.68%
C: -2.46%
treatment nephropathy topline positive phase 2
The Worldwide Paroxysmal Nocturnal Hemoglobinuria Treatment Industry is Expected to Reach $4.7 Billion by 2027
Published: 2022-03-23 (Crawled : 13:30) - prnewswire.com
TMO | News | $548.38 0.66% 0.29% 1.5M
|
Health Technology
|
| O: -1.66%
H: 0.0%
C: 0.0%
NVS | News | $95.12 0.81% -1.18% 2.4M
|
Health Technology
|
| O: -0.6%
H: 0.0%
C: 0.0%
JNJ | News | $149.12 0.82% 0.0% 9.3M
|
Health Technology
|
| O: -0.38%
H: 0.0%
C: 0.0%
ALNY | $145.78 0.95% 0.94% 390K
|
Health Technology
|
| O: -0.59%
H: 1.0%
C: -0.32%
treatment
Alnylam Announces U.S. Food and Drug Administration Acceptance of Supplemental New Drug Application for OXLUMO® for the Treatment of Advanced Primary Hyperoxaluria Type 1
Published: 2022-03-01 (Crawled : 16:00) - biospace.com/
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: -3.33%
H: 0.0%
C: 0.0%
SNY | News | $47.125 1.78% 1.75% 2.1M
|
Health Technology
|
| O: -1.3%
H: 0.0%
C: 0.0%
ALNY | $145.78 0.95% 0.94% 390K
|
Health Technology
|
| O: 0.65%
H: 3.47%
C: 2.28%
oxlumo new drug treatment application drug food
Soleo Health to Administer OXLUMO™ for the Treatment of Primary Hyperoxaluria Type 1
Published: 2022-01-11 (Crawled : 15:00) - biospace.com/
ALNY | $145.78 0.95% 0.94% 390K
|
Health Technology
|
| O: -0.31%
H: 0.0%
C: 0.0%
treatment
Alnylam Submits CTA Application for ALN-APP, an Investigational RNAi Therapeutic for the Treatment of Alzheimer’s Disease and Cerebral Amyloid Angiopathy
Published: 2021-12-22 (Crawled : 13:00) - biospace.com/
SNY | News | $47.125 1.78% 1.75% 2.1M
|
Health Technology
|
| O: -0.59%
H: 1.12%
C: 0.93%
ALNY | $145.78 0.95% 0.94% 390K
|
Health Technology
|
| O: -5.24%
H: 2.44%
C: -0.93%
alzheimer treatment application disease alzheimer’s alzheimer's disease alzheimer's
Gainers vs Losers
| 75% | 25% |
Top 10 Gainers
MTTR | News M | $4.78 174.71% 63.6% 72M
|
AGBA | $2.565 105.2% 51.27% 200M
|
Finance
MLEC | $2.44 74.29% 42.62% 78M
|
n/a
EDBL | News | $6.28 67.02% 40.13% 16M
|
ATGL | $2.91 48.81% 32.8% 180K
|
ZAPP | $0.2175 47.16% 32.05% 16M
|
n/a
ONFO | $0.6075 38.38% 27.74% 7.3M
|
n/a
VIVK | $1.48 38.32% 27.7% 530K
|
Professional, Scientific, and T...
MNTS | $0.5 35.69% 26.3% 4.8M
|
SDIG A | $3.635 35.13% 26.0% 1M
|
Your saved searches
Save your searches and get alerts when important news are released.